CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company, is nearing the completion of its Phase 2 clinical trial for THIO-101, a treatment candidate for non-small cell lung cancer (NSCLC). The company announced that updates on survival and response data from the trial are expected to be released soon.
The trial is part of MAIA's broader research into immuno-oncology therapies, targeting multiple types of hard-to-treat cancers. Beyond THIO-101, the company has developed over 80 compounds for a second-generation telomere targeting program.
The pipeline also includes THIO-102 and THIO-103, which are in the planning stages for Phase 2 and Phase 2/3 clinical trials, respectively, as well as Investigational New Drug (IND)-enabling studies for these second-generation agents.
MAIA's efforts are directed towards creating treatments with novel mechanisms of action that aim to significantly improve and extend the lives of patients with cancer. Their lead program, THIO, is described as a potential first-in-class telomere targeting agent for treating NSCLC patients with telomerase-positive cancer cells.
The company's shareholder letter, which provides more detail on these developments, is accessible through the Investor Relations section of MAIA's corporate website. As the company approaches significant milestones in its clinical trials, investors and industry watchers are anticipating the forthcoming data, which could potentially impact the company's direction and the broader landscape of cancer treatment options.
This news is based on a press release statement from MAIA Biotechnology, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.